It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Delivery of information to clinicians on evolving antimicrobial susceptibility needs to be accurate for the local needs, up-to-date and readily available at point of care. In northern Australia, bacterial infection rates are high but resistance to first- and second-line antibiotics is poorly described and currently-available datasets exclude primary healthcare data. We aimed to develop an online geospatial and interactive platform for aggregating, analysing and disseminating data on regional bacterial pathogen susceptibility. We report the epidemiology of Staphylococcus aureus as an example of the power of digital platforms to tackle the growing spread of antimicrobial resistance in a high-burden, geographically-sparse region and beyond. We developed an online geospatial platform called HOTspots that visualises antimicrobial susceptibility patterns and temporal trends. Data on clinically-important bacteria and their antibiotic susceptibility profiles were sought from retrospectively identified clinical specimens submitted to three participating pathology providers (96 unique tertiary and primary healthcare centres, n = 1,006,238 tests) between January 2008 and December 2017. Here we present data on S. aureus only. Data were available on specimen type, date and location of collection. Regions from the Australian Bureau of Statistics were used to provide spatial localisation. The online platform provides an engaging visual representation of spatial heterogeneity, demonstrating striking geographical variation in S. aureus susceptibility across northern Australia. Methicillin resistance rates vary from 46% in the west to 26% in the east. Plots generated by the platform show temporal trends in proportions of S. aureus resistant to methicillin and other antimicrobials across the three jurisdictions of northern Australia. A quarter of all, and up to 35% of methicillin-resistant S. aureus (MRSA) blood isolates in parts of the northern Australia were resistant to inducible-clindamycin. Clindamycin resistance rates in MRSA are worryingly high in regions of northern Australia and are a local impediment to empirical use of this agent for community MRSA. Visualising routinely collected laboratory data with digital platforms, allows clinicians, public health physicians and guideline developers to monitor and respond to antimicrobial resistance in a timely manner. Deployment of this platform into clinical practice supports national and global efforts to innovate traditional disease surveillance systems with the use of digital technology and to provide practical solutions to reducing the threat of antimicrobial resistance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Charles Darwin University, Menzies School of Health Research, Global & Tropical Health, Darwin, Australia (GRID:grid.1043.6) (ISNI:0000 0001 2157 559X)
2 Queensland Health, Communicable Diseases Branch, Brisbane, Australia (GRID:grid.415606.0) (ISNI:0000 0004 0380 0804)
3 Northern Territory Government, Territory Pathology, Darwin, Australia (GRID:grid.483876.6) (ISNI:0000 0004 0394 3004)
4 Griffith University School of Medicine, Pathology Queensland Central Laboratory, Brisbane, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
5 Telethon Kids Institute, University of Western Australia, Wesfarmers Centre of Vaccines and Infectious Diseases, Perth, Australia (GRID:grid.1012.2) (ISNI:0000 0004 1936 7910); Perth Children’s Hospital, Department of Infectious Diseases, Perth, Australia (GRID:grid.410667.2) (ISNI:0000 0004 0625 8600); PathWest Laboratory Medicine, Perth, Australia (GRID:grid.2824.c) (ISNI:0000 0004 0589 6117)
6 Charles Darwin University, Menzies School of Health Research, Global & Tropical Health, Darwin, Australia (GRID:grid.1043.6) (ISNI:0000 0001 2157 559X); The Royal Melbourne Hospital and Doherty Department University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victorian Infectious Disease Service, Melbourne, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X)
7 Charles Darwin University, Menzies School of Health Research, Global & Tropical Health, Darwin, Australia (GRID:grid.1043.6) (ISNI:0000 0001 2157 559X); Royal Darwin Hospital, Department of Infectious Diseases, Darwin, Australia (GRID:grid.240634.7) (ISNI:0000 0000 8966 2764)